Drug Database
DR

drug delivery system

✓ Approved

Titan Pharmaceuticals, Inc. · 治疗药物

什么是 drug delivery system?

drug delivery system 是一种治疗药物,由Titan Pharmaceuticals, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Surgical Implantation。

药物档案

公司Titan Pharmaceuticals, Inc.
给药途径Surgical Implantation
状态Approved

治疗适应症

drug delivery system 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresOral appliance application✓ Approved

相关研究文献

PubMedAdvanced healthcare materials2026-11-17

Microparticle-Enabled Local Sustained Delivery of Paroxetine for Osteoarthritis Treatment.

Kim Jung Hwan JH, Haj Shehadeh Tarek T, Ataie Zaman Z, Jaberi Arian A et al.

Osteoarthritis (OA) is a prevalent joint disease characterized by irreversible cartilage degradation, chronic pain, and reduced quality of life. Current treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, are largely palliative, ineffective for some patients, and associated with adverse effects. We have shown that paroxetine (Px), an FDA-approved antidepressant, has potential as a disease-modifying OA drug by inhibiting the G protein-coupled receptor kinase 2 (GRK2). Elevated GRK2 activity drives inflammation, extracellular matrix degradation and cartilage damage in OA. By inhibiting GRK2, Px suppresses cartilage degeneration, enhances chondrocyte anabolic activity, and reduces inflammation in the OA joint. In this study, we develop a local, slow-release drug delivery system that harnesses the therapeutic benefits of Px for OA treatment via microfluidic-assisted encapsulation in size-controlled poly(lactic-co-glycolic acid) (PLGA) microparticles (MP). In vitro studies show that the drug release profile is controlled by tuning the MP fabrication parameters. Efficacy testing shows that Px-eluting PLGA microparticles (MP-Px) decrease fibroblast cell migration and proliferation in vitro. In vivo, the intra-articular implantation of MP-Px in the clinically relevant destabilization of medial meniscus mouse OA model decreases chondrocyte apoptosis and has some anti-inflammatory effects in the acute phase of OA. Safranin O staining indicates mild staining loss in MP-treated groups, warranting further assessment of cartilage-matrix safety with long-term use. Importantly, serum Px levels remain low following MP-Px treatment compared with intraperitoneally administered Px (IP-Px). To the best of our knowledge, this biomaterial provides the first local intra-articular delivery of Px. These short-term findings in mice support further preclinical evaluation of MP-Px, including its effects on the cartilage matrix and long-term efficacy.

PMID 43040906
阅读全文 →
PubMedBiomaterials research2026-11-17

Visible Light-Active Hyaluronic Acid Dermal Fillers for User-Demand Quick Molding and Local Drug Delivery.

Jang Sangsoo S, Kang Hyeon-Gu HG, Lee Sung Oh SO, Kim Semin S et al.

Injectable dermal fillers are increasingly used for tissue augmentation and local drug delivery, but conventional particulate fillers often require high injection forces, pose a risk of vascular occlusion, and offer limited moldability. Here, we report a visible light-responsive hyaluronic acid liquid dermal filler (HA photofiller) that enables on-demand molding and localized delivery of regenerative agents through biocompatible in-body photocrosslinking. The HA photofiller was prepared as a low-viscosity photocrosslinkable HA precursor that rapidly formed a mechanically stable hydrogel after short visible light exposure. Its liquid state allowed low-force injection (<3 N through a 27-gauge needle) and shaping before fixation, while the photocrosslinked hydrogels exhibited concentration-dependent mechanical tunability. Incorporation of α-ketoglutarate, selected as a regenerative agent that promotes collagen synthesis in dermal fibroblasts, enhanced dermal collagen deposition in vivo. The HA photofiller achieved rapid in situ fixation after molding, minimal initial swelling, excellent biocompatibility, and long-term volume maintenance (~90% retention over 28 d). In a rabbit ear intra-arterial injection model, the HA photofiller exhibited rapid vascular washout without visible signs of persistent vascular occlusion or ischemic tissue injury. By integrating on-demand moldability, improved vascular safety, and localized regenerative activity, this light-responsive HA photofiller provides a versatile platform for next-generation aesthetic and regenerative medicine applications.

PMID 43041595
阅读全文 →
PubMedInternational journal of nanomedicine2026-11-17

Key Role and Translational Challenges of Lipid-Based Nanomedicine for Effective Prostate Cancer Therapy.

Mehri Sara S, Shourian Mostafa M, Kheirkhah Amir Hossein AH, Reihani Nasim N

Surface-engineered lipid-based nanocarriers (LBNs) have been widely investigated as drug-delivery systems for prostate cancer (PC) and may improve drug delivery while reducing systemic toxicity. Despite promising preclinical findings, their clinical translation for PC remains limited. This critical narrative review examines the biological, pharmacological, technological, and clinical barriers that may explain the gap between preclinical performance and clinical application. It focuses on PC-specific challenges, including androgen receptor (AR) alterations, marked intratumoral heterogeneity, a dense and immunosuppressive tumor microenvironment (TME), and the distinctive bone-metastatic niche. The review also situates LBNs within the context of alternative therapeutic approaches, including antibody-drug conjugates (ADCs) and proteolysis-targeting chimeras (PROTACs), highlighting their complementary capabilities and limitations. Building on this analysis, we outline a biology-driven framework to guide the development of next-generation LBNs. The framework comprises three priorities: (1) biomarker-guided combination targeting of heterogeneous tumor-cell populations, including phenotypically plastic cancer stem cells (CSCs); (2) disease-site-specific, sequential strategies to modify the TME and improve drug transport in soft-tissue tumors and bone metastases; and (3) integration of circulating biomarkers, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), with spatial and molecular imaging, such as multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT), to inform formulation selection. By connecting nanocarrier design with PC biology and clinical constraints, this review identifies priorities for evaluating the translational potential of LBNs for advanced PC.

PMID 43042234
阅读全文 →
PubMedCurrent protocols2026-11-17

Production, Drug Loading, and Therapeutic Delivery of Macrophage-Engineered Vesicles Via Nitrogen Cavitation.

Nagle Julia J, Daniel Noah I NI, Dorosh Alina V AV, Cao Connie D CD et al.

Endogenously produced engineered vesicles (EVs) serve many important signaling and regulatory functions in vivo, resulting in investigations into their utility as targeted therapeutic delivery vehicles. Unfortunately, the practicality of using endogenous EVs therapeutically is limited by the small number of EVs that are produced naturally. Therefore, researchers have focused on engineering artificial EVs at significantly higher yields and from a variety of cell sources. These artificial EVs have potential therapeutic effects on their own as well as the ability to serve as a means of localized drug delivery. Vesicles originating from immune cells such as macrophages are particularly attractive as these cells function in tissue repair, development, and are a critical component of the tumor microenvironment in many cancers. Macrophages are classically polarized into M1 and M2 phenotypes, where M1 cells drive pro-inflammatory responses, and M2 cells promote tissue repair. In the tumor microenvironment, tumor-associated macrophages (TAMs) are in an M2-like immunosuppressive state that supports cancer growth. Reprogramming M2 TAMs to an M1 state has shown promise as a novel cancer treatment strategy. We have developed a process to manufacture EVs from M1 macrophages that can reprogram M2 macrophages to an M1 state. Additionally, we are also capable of loading these vesicles with chemotherapeutics to enhance their anti-tumor effects. The anti-cancer efficacy of these engineered vesicles was tested both in vitro and in vivo in a murine ovarian cancer xenograft model. © 2026 Wiley Periodicals LLC. Basic Protocol 1: Manufacturing vesicles via nitrogen cavitation Alternate Protocol: Manufacturing cisplatin-loaded vesicles Support Protocol 1: Macrophage cell reprogramming Support Protocol 2: Vesicle characterization Support Protocol 3: Measuring cisplatin concentration in vesicles by mass spectrometry Basic Protocol 2: Measuring macrophage reprogramming and anti-tumor activity in vitro Basic Protocol 3: Intraperitoneal delivery of vesicles for in vivo treatment.

PMID 43042863
阅读全文 →
PubMedPediatric obesity2026-11-17

Supporting the Sustained Delivery of an Early Life Health Behaviour Program at Scale: A Qualitative Study of INFANT Implementation Strategies.

Katiforis Ioanna I, Laws Rachel R, Duric Della D, Spiteri Sheree S et al.

Early life is critical for preventing childhood overweight and obesity. INfant Feeding, Active play and NuTrition (INFANT) is an evidence-based health behaviour program supporting parents with infant feeding and active play, delivered at scale in Victoria, Australia. This study explored the perspectives of INFANT-trained coordinators and facilitators, focusing on implementation strategies supporting at-scale sustained delivery. A multi-site qualitative exploratory study was conducted (2022-2024). Semi-structured interviews were undertaken with coordinators and facilitators at 12- and 24-months post-training. Transcripts were analysed thematically using a hybrid deductive-inductive approach, guided by the Implementation Strategies Applied in Communities framework. 19 participants from 15 of 41 local government areas with sustained INFANT delivery (7 metropolitan, 8 regional) provided insights. Fourteen implementation strategies supporting sustained delivery were identified and organised into five themes: (1) equipping and supporting facilitators; (2) leveraging opportunities, partnerships and funding; (3) providing structured guidance and resources; (4) adapting and tailoring the program; and (5) monitoring delivery through pragmatic evaluation. Participants perceived implementation strategies as important for sustaining delivery. Most relied on individual and organisational efforts and were constrained by inconsistent and inadequate funding and limited workforce capacity. System-level strategies including embedded implementation support are needed to optimise INFANT sustainment.

PMID 43040910
阅读全文 →
PubMedACS nano2026-11-17

Structure-Engineered Lipid-Mineral Nanoparticles for Ligand-Free Myeloid RNAi Delivery in Alzheimer's Disease.

Shi Kexin K, Zhang Chenyun C, Chen Yaoxing Y, Li Haixia H et al.

Peripheral myeloid cells are key regulators of systemic inflammation and promising targets for immune intervention in Alzheimer's disease (AD). However, selective in vivo small interfering RNA (siRNA) delivery to these cells remains challenging because conventional lipid nanoparticles often exhibit predominant hepatic accumulation and usually require ligand or antibody modification for immune-cell targeting. Here, we report a structure-engineered lipid-mineral nanoparticle platform, termed MCP, for ligand-free myeloid RNA interference (RNAi) delivery. MCP integrates a calcium phosphate mineral phase with a phosphatidic acid-enriched lipid interface, enabling efficient siRNA incorporation. The Ca2+-lipid cooperative architecture promoted macropinocytosis-dependent uptake and preferential siRNA delivery to peripheral myeloid cells in vivo, particularly Ly6Chigh monocytes and macrophages, with enhanced delivery under AD-associated inflammatory conditions. Systemic delivery of MCP carrying siRNA against triggering receptor expressed on myeloid cells 1 (TREM1) attenuated neuroinflammatory and neurodegenerative pathology in an AD mouse model, supporting peripheral myeloid reprogramming as a route to modulate central nervous system (CNS) disease progression. Notably, MCP also achieved efficient TREM1 silencing in AD patient-derived peripheral blood mononuclear cells (PBMCs) and restored TREM1 expression toward healthy-control levels. This work establishes a structure-driven, ligand-free lipid-mineral RNAi platform for peripheral immune intervention in AD.

PMID 43043232
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多drug delivery system